Prognostic Factors of Peritoneal Metastases from Colorectal Cancer following Cytoreductive Surgery and Perioperative Chemotherapy

Background. Prolonged survival of patients affected by peritoneal metastasis (PM) of colorectal origin treated with complete cytoreduction followed by intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) has been reported. However, two-thirds of the patients after complete cytoreduction and perioperative chemotherapy (POC) develop recurrence. This study is to analyze the prognostic factors of PM from colorectal cancer following the treatment with cytoreductive surgery (CRS) + POC. Patients and Methods. During the last 8 years, 142 patients with PM of colorectal origin have been treated with CRS and perioperative chemotherapy. The surgical resections consisted of a combination of peritonectomy procedures. Results. Complete cytoreduction (CCR-0) was achieved at a higher rate in patients with peritoneal cancer index (PCI) score less than 10 (94.7%, 71/75) than those of PCI score above 11 (40.2%, 37/67). Regarding the PCI of small bowel (SB-PCI), 89 of 94 (91.5%) patients with ≤2 and 22 of 48 (45.8%) patients with SB-PCI ≥ 3 received CCR-0 resection (P < 0.001). Postoperative Grade 3 and Grade 4 complications occurred in 11 (7.7%) and 14 (9.9%). The overall operative mortality rate was 0.7% (1/142). Cox hazard model showed that CCR-0, SB-PCI ≤ 2, differentiated carcinoma, and PCI ≤ 10 were the independent favorite prognostic factors. Conclusions. Complete cytoreduction, PCI, SB-PCI threshold, and histologic type were the independent prognostic factors.

[1]  Y. Yonemura,et al.  Effects of Neoadjuvant Intraperitoneal/Systemic Chemotherapy (Bidirectional Chemotherapy) for the Treatment of Patients with Peritoneal Metastasis from Gastric Cancer , 2012, International journal of surgical oncology.

[2]  D. Sargent,et al.  Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  V. Verwaal Long-Term Results of Cytoreduction and HIPEC Followed by Systemic Chemotherapy , 2009, Cancer journal.

[4]  Henry C. Pitot,et al.  Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Morris,et al.  Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Isolated Colorectal Peritoneal Carcinomatosis: Experimental Therapy or Standard of Care? , 2008, Annals of surgery.

[6]  B. Griffith,et al.  Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Isolated Colorectal Peritoneal Carcinomatosis: Experimental Therapy or Standard of Care? , 2008, Annals of surgery.

[7]  J. Esquivel,et al.  Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination , 2008, Journal of surgical oncology.

[8]  P. Sugarbaker,et al.  Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. , 2006, Journal of the American College of Surgeons.

[9]  M. Ducreux,et al.  Peritoneal carcinomatosis of colorectal origin. , 2006, Gastroenterologie clinique et biologique.

[10]  M. Ducreux,et al.  Peritoneal carcinomatosis of colorectal origin Long-term results of intraperitoneal chemohyperthermia with oxaliplatin following complete cytoreductive surgery , 2006 .

[11]  F. Kwiatkowski,et al.  Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Cotte,et al.  Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin , 2004, The British journal of surgery.

[13]  H. van Tinteren,et al.  Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy , 2004, The British journal of surgery.

[14]  M. Pocard,et al.  Treatment of Peritoneal Carcinomatosis From Colorectal Cancer: Impact of Complete Cytoreductive Surgery and Difficulties in Conducting Randomized Trials , 2004, Annals of Surgical Oncology.

[15]  H. van Tinteren,et al.  Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Mocellin,et al.  Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Intraoperative Chemotherapy for Peritoneal Carcinomatosis Arising From Colon Adenocarcinoma , 2003, Annals of Surgical Oncology.

[17]  D. Jayne,et al.  Peritoneal carcinomatosis from colorectal cancer , 2002, The British journal of surgery.

[18]  P. Sugarbaker,et al.  Successful management of microscopic residual disease in large bowel cancer , 1999, Cancer Chemotherapy and Pharmacology.

[19]  P. Sugarbaker,et al.  Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. , 1996, Cancer treatment and research.

[20]  K. Westbrook,et al.  Peritioneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors , 1989, Cancer.